Blue Matter

NEW: 5 key dynamics shaping the market for buy and bill drugs >> bit.ly/4bqu2H1

A look at the global #CDMO market & the opportunities, risks, & investment playbook for private equity >> bit.ly/4azkjyZ

10 Critical Success Factors for Launching & Commercializing Cell & Gene Therapies >> bit.ly/4aRvkvn #pharmaceutical #biotech #celltherapies #genetherapies #celltherapy #genetherapy

4 trends that will drive change in #RareDisease therapies in 2026 & beyond >> bit.ly/4abOH28 #RareDiseases #biotech #pharmaceuticals #biopharma

NEW >> 10 critical success factors for launching & commercializing cell / gene therapies >> bit.ly/4kvOwCk

#CNS market outlook for 2026 & beyond (biopharma R&D, commercialization) >> bit.ly/3O0BvEK

A look at opportunities, risks, and PE investment strategies in the global #CDMO market >> bit.ly/4cmICRP

It's time for our annual #oncology market outlook. Here are 7 key trends that will shape the market in 2026 & beyond >> bit.ly/4bykrzB

#CNS Market Outlook >> We identify 5 key trends that will shape the CNS market in 2026 >> bit.ly/3NXJMJq #biotech #pharmaceuticals #CentralNervousSystem #alzheimers #psychedelics

@ideapharma The image connotes a "balance" of RISK (on the top) and RETURN on the bottom (to which the RN belongs). Note how the blocks are balanced on their edges. Always more than one way to interpret an image.

@BlueMatter1 I know I'm being pedantic (competitor 😅), but the graphic is confusing me - return makes sense, but riskrn?

Most single-asset #biopharma companies will expand to build a portfolio of therapeutic assets. In this paper, we offer some insights regarding portfolio forecasting, prioritization, & management >> bit.ly/4kcqv2Y

Another excellent JPM with plenty of great client conversations. We look forward to following up & supporting them through these changing times. P.S. - You can’t beat a good Chinese meal at midnight after a long few days :) #JPMorganHealthcareConference #JPM2026

How #biopharma can get the most value from #ArtificialIntelligence in R&D >> bit.ly/3YCLS3y

Last month, Blue Matter team members attended #ISPOREurope in Glasgow. In this article, we explore 5 key topics of discussion from the conference, including the impact of US policy changes, JCA implications, #ArtificialIntelligence, & more >> bit.ly/44d6NgJ #HEOR

The US #biopharma #MarketAccess landscape has been volatile during 2025. In this latest article, we explore the factors that are driving uncertainty. Plus, we provide a look ahead to 2026 >> bit.ly/47rEzQ3 #MFNDrugPricing #biotech #pharmaceuticals

Speed has always been an important factor in #pharmaceutical commercialization. In this paper, we share common factors that can act as "brakes" on companies, plus a framework for building speed without sacrificing quality >> bit.ly/3L9ngvR #biotech #pharmaceuticals

NEW > In #RareDiseases, finding patients can be quite a challenge. In this case study, Eric Vogel & Nikhil Bhat show how #MachineLearning can make the job easier >> bit.ly/4hiKhbO #biopharma #biotech #pharmaceutical #raredisease #patientfinding

NEW >> What methods can growing #biopharma companies use to optimize investments across a diverse portfolio of assets or programs? In this article, we address that question & explore how #decisionscience can help >> bit.ly/3IXfK6y #biotech #pharmaceuticals

New #WhitePaper: We look back at the 1st half of 2025 to examine how the current #biopharma deal-making environment compares with prior periods. We explore key statistics around deal size & volume, deal types, therapeutic areas of interest, & more. >> bit.ly/42Y1Wzm

Recently, Blue Matter's Jenna Riffell attended the annual Congress of the @eadv in Paris. In this article, Jenna identifies some key themes from the meeting & offers insights on the #dermatology market bit.ly/4pICrvI #biotech #pharmaceuticals #eadv25